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miR302 regulates SNAI1 expression 
to control mesangial cell plasticity
Letizia De Chiara1,2,3, Darrell Andrews1,2, Ariane Watson2, Giorgio Oliviero2,4, Gerard Cagney2 
& John Crean1,2
Cell fate decisions are controlled by the interplay of transcription factors and epigenetic modifiers, 
which together determine cellular identity. Here we elaborate on the role of miR302 in the regulation of 
cell plasticity. Overexpression of miR302 effected silencing of the TGFβ type II receptor and facilitated 
plasticity in a manner distinct from pluripotency, characterized by increased expression of Snail. 
miR302 overexpressing mesangial cells also exhibited enhanced expression of EZH2 coincident with 
Snail upregulation. esiRNA silencing of each component suggest that Smad3 and EZH2 are part of a 
complex that regulates plasticity and that miR302 regulates EZH2 and Snail independently. Subsequent 
manipulation of miR302 overexpressing cells demonstrated the potential of using this approach 
for reprogramming as evidenced by de novo expression of the tight junction components ZO-1 and 
E-cadherin and the formation of ZO-1 containing tight junctions. Understanding the processes through 
which dynamic epigenetic silencing is controlled in adults cells will allow us to address the epigenetic 
state of acquired disease and whether original states, regenerative in nature, can be restored with 
therapy.
Diabetes mellitus is a complex metabolic disorder, the 5th leading cause of mortality worldwide resulting in more 
than 4 million deaths annually. Recent reports have predicted a 150% increase in occurrence in the next 20 years, 
with a major burden on medicinal care due to its devastating complications1. Diabetic nephropathy (DN) is a 
common complication of diabetes, with 25–45% of patients developing renal fibrosis and progressing to end 
stage renal disease2. There is no cure for DN and therapeutic efforts are focused on limiting loss of renal function 
and associated symptoms3. During the last fifteen years, significant advances have been made concerning the 
mechanisms underlying initiation and progression of chronic kidney disease. The capacity of renal mesangial 
cells to undergo remodelling and acquire fibroblastic plasticity was first suggested by studies from our labora-
tory that identified the recapitulation of ontogenic gene expression profiles in experimental models of diabetic 
nephropathy and in patients4 (Supplementary Fig. S1). Subsequent studies have extensively characterised the role 
of Transforming Growth Factor β 1 (TGFβ 1) in mediating these change however despite significant efforts in this 
area, therapeutic interventions have yet to demonstrate clinical efficacy. New paradigms are emerging from recent 
studies elucidating the instructive role of TGFβ during embryonic development, coupled with the identification 
of parallel processes in adult tissues5.
Cell fate specification is a progressive process of diversification through which a cell, by undergoing profound 
changes in gene expression and regulation, takes its role within a defined context. On the other hand, cell fate con-
version is considered a process by which a cell can change its phenotype and acquire a new and distinct “altered” 
fate6. While the first process is pivotal during development, the latter is increasingly recognized as fundamental 
not only during embryogenesis but also in numerous disease states7,8. A cell must acquire a plastic phenotype in 
order to properly adapt and respond to environmental stimuli. These adapting processes involve and are con-
trolled by the interplay between microRNAs, transcription factors (TFs), and epigenetic modifiers that work in 
concert to determine cell fate.
Human Mesangial Cells (HMCs) are a specialized type of microvascular pericyte9 anchored to the glomer-
ular membrane. Due to their intrinsic nature, these cells are highly plastic and responsive to the surrounding 
microenvironment. These responsive mechanisms often result in detrimental processes being triggered by extra-
cellular stimuli that can lead to the destruction of the complex glomerular and renal ultrastructure10. Frequently, 
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these alterations result in a change in cytoskeletal-mediated contractility, reflected in dynamic focal adhesions11. 
Perhaps this is best evidenced by the apparent alterations in actin dynamics mediated by TGFβ and CTGF, reflect-
ing changes in contractility both in vivo and in vitro; previous studies carried out in our laboratory have demon-
strated that HMCs acquire plasticity triggered by hyperglycaemia and growth factors4 which greatly enhances 
the expression of a family of microRNAs, the miR302 family. The miR302 family is composed of 4 members, 
miR302a/b/c/d that are transcribed as a single polycistronic cluster12; this cluster is prominently expressed in 
Embryonic Stem Cells (ESCs) while its expression is decreased during differentiation and commitment13. It has 
been previously shown that miR302 can promote iPSC (induced Pluripotent Stem Cells) generation14–16 and its 
expression is directly regulated by the stemness factors, Oct4 and Sox2, and Nanog17,18.
The primary validated target of miR-302 is the Transforming Growth Factor (TGF)-β Type II receptor 
(Tβ RII)14. TGFβ has a prominent role in triggering Epithelial to Mesenchymal Transition (EMT) during embryo-
genesis and activating parallel processes in disease19. Strikingly, miR302 is able to control and impact on the TGFβ 
pathway in an extensive and context-dependent manner; it has a well-established role in promoting the acquisi-
tion of pluripotency by targeting the Tβ RII, thus blocking the activation of the pathway12,14, however it can also 
propagate and promote its activation in ESCs by levelling the expression of LEFTY120.
The identification of embryonic stem cell specific miRNAs led to the widely accepted hypothesis that interplay 
between specific microRNAs and their repressed targets controls both the maintenance of stemness and the spec-
ification of cell types21,22. Increasingly, parallel processes in pathogenesis are recognised as critical mediators of 
damage and repair. Specifically, the potential role of the miR302 and Let-7 families in both these processes have 
been recently established by our group and others4,23.
In addition to these processes, a third level of regulation, involving the remodelling of the chromatin envi-
ronment, has emerged as numerous studies have demonstrated that cell type specific regulatory genes can be 
identified by specific histone marks24. Among others, changes in the methylation status of histone H3 have been 
associated with stemness, cell specification and numerous diseases25,26. The methylation of histone H3 on the 
lysine 4 (H3K4) and and 26 (H3K26) are generally associated with active transcription27, whereas permissive 
promoters are enriched with both active (H3K4) and repressive marks (H3K27) and considered to exist in a 
“poised” state27,28. Central to these processes is the Polycomb Repressive Complex 2 (PRC2), which contains 
EZH2 (Enhancer of zeste homolog 2), a histone methyltransferase that catalyzes the trimethylation of H3K2729, 
mediating gene repression, and additional core components EED, SUZ12 and RBBP4/RbAp48/NURF55.
In the present study we investigated the role of miR302 in regulating mesangial plasticity and explore the idea 
that partial reprogramming of mesenchymal cells leads to the acquisition of a “poised” state that may be manip-
ulated for therapeutic repair.
Results
Overexpression of miR302a/b/c/d in Human Mesangial Cells. HMCs were seeded at a very low 
confluency and then incubated for 48 h with a polycistronic lentiviral vector encoding all four members of the 
miR302 family and a Green Fluorescent Protein (GFP)-reporter. At 7 days post transduction all cells demon-
strated clear GFP expression (Fig. 1A). The expression of the miR302d was analysed by RealTime PCR as a 
readout of the level of expression of miR302 in the cells. 7 days post lentiviral transduction, a marked increase in 
miR302d expression (Fig. 1B) was observed, indicating successful transduction. RNA and protein were extracted 
at various time points in order to investigate the phenotypic changes caused by the miR302 overexpression sys-
tem. One of the best-characterised targets of the miR302 family is the Tβ RII4,14. Tβ RII is involved in EMT and its 
activation leads to the phosphorylation of Smad2 and Smad3 resulting in their translocation from the cytoplasm 
to the nucleus30. We verified the effective downregulation of Tβ RII by both RNA (Fig. 1C) and protein analysis 
(Fig. 1D). As expected, the receptor is repressed throughout all time points. miR302 is the most important and 
abundant microRNA present in human ESCs (hESCs)12. Since its promoter can be directly bound and regulated 
by Oct417,18 and various reports have highlighted its ability to induce Oct4 expression16, we investigated whether 
miR302 overexpression caused the acquisition of a pluripotent phenotype in HMCs. RealTime PCR analysis 
for Oct4 and Nanog was performed at various time points (Supplementary Fig. S2) showing no expression of 
either transcription factors. Noticing the appearance of rounded granulated colonies between 14 and 21 days 
post-transduction, we hypothesised that these colonies originated from HMCs cells successfully reprogrammed 
toward pluripotency. After picking, HMC-derived colonies were cultured on matrigel under stem cell-like con-
ditions for up to 21 days. These colonies were able to attach to the coated plates and proliferate. Although they 
became bigger and tried to divide (Supplementary Fig. S3A), no obvious hallmarks of a pluripotent phenotype 
were observed nor was there any significant change in Oct4 expression (Supplementary Fig. S3B). Taken together, 
these results demonstrated the successful transduction of HMCs with miR302 lentivirus and its ability to block 
Tβ RII expression. Moreover, they showed that miR302 upregulation alone is not sufficient to reprogram HMCs 
to pluripotency.
miR302 upregulates Snail expression in HMCs. Having verified the lack of pluripotency in 
miR302-HMCs, we proceeded to analyse the phenotype acquired by the cells. Interestingly, increased expression 
of Snail (or SNAI1) was consistently observed at 3 days and 7 days post transduction in miR302 overexpressing 
cells, although some variability in levels were apparent, likely reflecting the heterogeneous and asynchronous 
nature of the cell populations at these time points. (Figure 2A,B, quantified in Supplementary Fig. S4A). We 
verified that this upregulation was not due to a nonspecific effect by analysing the resulting Snail expression 
in an additional arbitrarily chosen cell type (Supplementary Fig. S5A) after miR302 overexpression. This was 
a particularly unexpected result as Snail is widely regarded as the most important transcription factor involved 
in driving EMT as a result of Tβ RII/Tβ RI activation. No increased expression of Snail was apparent in HMCs 
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following TGFβ treatment (Supplementary Fig. 5B) and additionally, they also exhibited downregulation of 
miR302 (Supplementary Fig. 5C), supporting the idea that Snail is not regulated by TGFβ in this context.
To rule out the possibility that Snail expression was linked to an alternative mechanism of activation of 
the TGFβ Receptor I (Tβ RI) we treated miR302-HMCs with a potent and specific inhibitor of the receptor31, 
SB431543, 7 days post miR302 transduction. After 7 and 14 days of treatment with the inhibitor (Fig. 2C, quanti-
fied in Supplementary Fig. S4B,C) the cells maintained a high level of Snail protein expression, comparable to the 
standard culture condition (Fig. 2C). Similarly, Snail mRNA expression is maintained throughout the 2 weeks of 
treatment with the inhibitor (Supplementary Fig. S4D). A recent study from the Daley laboratory demonstrated 
that Snail is paradoxically required in order to successfully reprogram fibroblasts to pluripotency32. They showed 
how Snail promotes the acquisition of plasticity by binding the promoter of the Let-7 family of microRNAs, thus 
causing its downregulation. This hypothesis is particularly fascinating when considering the reciprocal relation-
ship that occurs between miR302 and Let-713. In order to verify whether this mechanism is valid in this context, 
we measured the levels of two members of the Let-7 family, Let-7a and Let-7c, 7 days post transduction. Although 
the levels were lower in miR302 cells when compared to scramble cells, no statistically significant difference was 
detected (Fig. 2D), demonstrating that Snail in this context does not suppress Let-7 expression.
These results demonstrated, for the first time, that miR302 drives Snail expression in HMCs, during the acqui-
sition of plasticity.
EZH2 upregulation in miR302-HMCs is independent from Snail activation. As Snail plays a role 
in enhancing the acquisition of pluripotency in fibroblasts32 and pathogenic plasticity during renal failure33, we 
analysed the expression of other proteins known to be involved in these processes. We verified that Slug (or 
SNAI2), another member of the Snail family is similarly upregulated within the first 2 weeks post transduction 
(Fig. 3A, quantified in Supplementary Fig. S6A). Intriguingly, miR302-HMCs also exhibited enhanced expression 
of EZH2 coincident with Snail upregulation. EZH2 is the catalytic subunit of the PRC2 Complex and it catalyses 
the trimethylation of the lysine 27 on histone H334; by doing so the PRC2 complex can repress gene transcription 
through the control of promoter access29. EZH2 has been widely studied as a protein implicated in cancer and 
metastatic progression and its upregulation is linked to an aggressive phenotype and to enhanced proliferation 
by cancer cells35. Interestingly, in miR302-HMCs, EZH2 showed the same expression pattern as Snail, being 
significantly upregulated within the first 2 weeks post transduction, while its expression subsequently decreases 
(Fig. 3A, quantified in Supplementary Fig. S6A). Of note, the H3K27 tri-methylation mark, a repressive mark 
produced by EZH2 activity, was unexpectedly decreased, irrespective of EZH2 upregulation. Moreover, no differ-
ence was detected across all the time points for SUZ12, another core component of the PRC2 complex (Fig. 3A, 
Figure 1. Overexpression of miR302a/b/c/d in Human Mesangial Cells silences the TGFβ type II receptor. 
(A) Representative images of GFP+ HMCs 7 days post transduction with miR302 (left panel) and scramble virus 
(right panel). Original magnification x100. 7 days post transduction, HMCs showed a marked upregulation of 
miR302d expression when compared to scramble infected cells (B). As a result of miR302 overexpression  
Tβ RII expression is decreased at mRNA (C) and protein (D) level, across all the analysed time points. Graph B 
and C and panel (D) are representative of 3 independent experiments. (SCR: scramble; NT: Non-treated cells; 
GFP: Green Fluorescent Protein; Tβ RII: TGFβ Receptor II; RQ: Relative Quantification normalized on 18 S for 
Tβ RII or RNU6B for miR302d; **P < 0.01).
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quantified in Supplementary Fig. S6A), suggesting a specific effect on EZH2 by miR302. Finally, we established 
the correct localization in the nuclear fraction of EZH2 and Snail (Supplementary Fig. S7). Interestingly, in 
miR302-HMCs the downregulation of Tβ RII by miR302 overexpression did not affect the localisation of Smad3 
in the nuclei (Supplementary Fig. S7), suggesting again a TGFβ independent effect of miR302 in HMCs. A recent 
paper from the Liang group, demonstrated that Snail expression in cancer cells is able to upregulate EZH2 by 
inhibiting miR101 expression36. As EZH2 and Snail expression appeared to be tightly linked, and taking into 
account the fact that Smad3 was still present regardless of the silencing of the TGFβ type II receptor, we decided 
to knock down EZH2, Snail and Smad3 in miR302-HMCs using esiRNA. At 7 days post transduction, when the 
HMCs showed a high level of expression of both EZH2 and Snail we knocked down Snail, EZH2 and Smad3 
respectively, while a scrambled off-target sequence was used as a control. Interestingly, only the Smad3 knock-
down resulted in the downregulation of EZH2 suggesting that the 2 proteins may form a cooperative, regulatory 
complex. Knock down of EZH2 does not affect Snail and vice versa (Fig. 3B). SUZ12 was used as an unrelated 
control for off-target effect. Taken together, these results demonstrated that miR302 regulates EZH2 and Snail 
expression independently.
miR302-HMCs do not acquire a cancer-like phenotype. Since cancer cells expressing high levels 
of EZH2 display a higher rate of proliferation37,38 we performed an MTT assay on miR302-HMCs. A first set 
of experiments was carried out by seeding miR302-HMCs at 7 days post transduction (Fig. 4A,B) finding, as 
expected, an increased rate of cell proliferation. Importantly, miR302 cells return to a normal proliferation rate 
once the expression of EZH2 started to drop (Fig. 4C,D). In order to understand whether the increased prolifer-
ation of HMCs was linked to EZH2 activity we treated the cells at the time of seeding with DZnep, an inhibitor 
of EZH2 catalytic activity39. By blocking the activity of EZH2 the cells no longer demonstrated any changes in 
proliferation (Fig. 4E).
Increased proliferation, together with upregulation of both EZH2 and Snail are accepted hallmarks of tumour-
igenesis and metastastic progression36, so we therefore investigated whether HMCs transduced with miR302 
acquired a cancer-like phenotype. A well-known transcription factor involved in tumour progression is NFκ B. 
NFκ B is interesting for a number of different reasons; it represents not only an important link between cancer and 
Figure 2. miR302 increases the expression of Snail during the acquisition of plasticity. (A) Demonstrates 
increased expression of Snail in miR302-HMCs compared to scramble HMCs. During the first week following 
miR302 overexpression in HMCs, Snail is upregulated at both mRNA (A) and protein level (B). Snail expression 
is not blocked by the addition to the culture media of the SB431545 (C), a potent inhibitor of TGFβ Receptor I 
(top panel) compared to standard culture conditions (bottom panel). Given the reciprocal nature of miR302 and 
Let-7 family expression and considering that Snail has been recently reported to bind and repress the promoter 
of the Let-7 family we analysed the level of expression of two of the components of this family, Let-7a and 
Let-7c, noticing no difference 7 days post transduction (D). All the figures are representative of 3 independent 
experiments. (*P < 0.05).
www.nature.com/scientificreports/
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inflammation40 but it is also known for its role as Snail activator promoting cancer aggressiveness41. Intriguingly, 
analysis of NFκ B expression by Western Blot (Fig. 5A, quantified in Supplementary Fig. S8), found that it is 
decrased in miR302-HMCs compared to scramble transduced HMCs. Moreover, no change in TGFβ expression 
was detected at any of the analysed time points (Fig. 5C).
In hESCs, miR302 inhibits tumorigenicity by controlling G1-S cell cycle transition and promoting p16/Ink4a 
upregulation42, a well-known tumour suppressor protein43. By doing so, the members of this family protect the 
pluripotent nature of hESCs, preventing them from giving rise to cancer formation. We analysed p16/Ink4a 
expression by RealTime PCR (Fig. 5B) and found, in line with the literature, that miR302 overexpression caused 
an upregulation of p16/Ink4a expression.
Finally, we investigated the involvement of miR302 in promoting/preventing apoptosis. miR302 has been 
shown to cause apoptosis in cancer cells44, while in normal cells it does not affect the apoptotic pathway42. To 
stimulate the activation of the apoptotic pathway in HMCs we treated the cells with etoposide, a potent anticancer 
drug capable of initiating a program of apoptosis45. As shown in in Fig. 5D, no difference was detected among 
the miR302, scramble and non-transduced groups regarding the appearance of the cleaved form of the caspase 3, 
while p53 upregulation is slightly diminished in miR302 and scramble cells compared to the non-transduced 
ones. This consistency, among the different groups, reflects the lack of an aggressive phenotype in miR302-HMCs.
These results are particularly important as they confirm that, although miR302-HMCs acquire a more-plastic 
phenotype, this process, in healthy cells, is not linked to a cancer-like state, raising the possibility that it can be 
used to manipulate cell fate and identity.
miR302-HMCs acquire plasticity that facilitates de novo assembly of ZO-1 containing junc-
tions. Taking these results together, miR302-HMCs exhibit a higher degree of plasticity, evidenced by Snail 
and EZH2 expression and their higher proliferation rate, when compared to scramble or control (non-transduced) 
HMCs.
In order to evaluate if this “positive” plasticity can be manipulated to push the cells toward a different, more 
epithelial phenotype, we devised a protocol employing a combination of two different inhibitors of GSK-3β 
and of the EZH2 activity respectively. DZnep was chosen as previous experiments carried out in our labora-
tory demonstrated a facility to increase E-cadherin expression in epithelial cells (Supplementary Fig. S9)46. 
Moreover, our group has demonstrated a role for EZH2 in supressing E-cadherin expression in the presence 
of Smad346 (Manuscript under submission). Similarly, GSK-3β inhibition has been shown to stabilize epithe-
lial junctions making ESCs more “epithelial”47. 12 days post miR302 transduction, when the cells exhibit the 
highest level of Snail and EZH2 expression, HMCs were plated on matrigel with the addition of the inhibitors. 
Within days of switching to a different microenvironment, miR302-HMCs started to acquire a more cobblestoned 
shape, (Fig. 6A), while scramble cells stopped proliferating and died. To assess the nature of these cobblestoned 
Figure 3. miR302 upregulates EZH2 independently from Snail expression, whereas Smad3 and EZH2 
demonstrate co-dependence. The expression of the PRC2 components was assessed at days 7, 14 and 21 post 
transduction (A). No changes were observed in SUZ12 across all the time points whereas EZH2 follows the 
same pattern as both Snail and Slug, another member of the Snail family. Of note, the trimethylation of lysine 
27 of histone H3, which is readout of the EZH2 activity, is unexpectedly turned off. EZH2, Snail and Smad3 
were knocked down using esiRNA technology in miR302-HMCs, demonstrating that EZH2 and Snail are 
independently upregulated by miR302 overexpression in HMCs (B). In contrast the Smad3 knock down results 
in decreased expression of EZH2 suggesting cooperativity between EZH2 expression and Smad3 (B). (NT: non-
transfected cells; H3K27me3: trimethylation of the lysine 27 on the histone H3). All panels are representative of  
3 independent experiments.
www.nature.com/scientificreports/
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cells we stained the miR302-HMCs for Zonula Occludens (ZO)-1, a protein contained in the tight junction. 
The miR302-HMCs, demonstrated de novo tight junction formation (white arrows, Fig. 6C), indicating that 
the cells have lost their characteristic scattered phenotype and formed connections with the surrounding cells. 
Figure 4. EZH2 expression correlates with increased proliferation of miR302-HMCs. mir302, scramble  
and non-transduced HMCs were seeded at a low confluency and an MTT assay was performed at 7 days  
(A) and 21 days (B) post transduction. Increased proliferation was observed 7 days post transduction 
correlating with the level of expression of EZH2 (B), while the proliferative advantage of miR302-HMCs is 
lost (C) when EZH2 expression decreases (D). This was confirmed by treating the cells with DZnep at the 
time of seeding (E); by ablating the activity of EZH2, the cells are no longer able to proliferate. All data are 
representative of 4 independent experiments performed separately. (DZnep: 3-Deazaneplanocin A, inhibitor of 
the EZH2 catalytic activity; **P < 0.01; ***P < 0.001).
www.nature.com/scientificreports/
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Interestingly, expression of the transcriptional repressor Snail was silenced in both miR302 and scramble cells 
after plating on matrigel (Fig. 6B). Finally, miR302-HMCs showed a statistically relevant upregulation of CDH1 
(E-cadherin) expression at mRNA level (Fig. 6D), in particular when treated with DZnep; overexpression of 
miR302 alone is not sufficient to trigger CDH1 expression.
These results demonstrated for the first time the de novo expression of epithelial junctions components by 
human mesangial cells demonstrating the potential of utilising such an approach for reprogramming in chronic 
renal disease.
Discussion
In the context of chronic renal diseases, TGFβ plays an important role in directing cellular damage in the DN 
milieu48. The TGFβ superfamily is composed of activins, nodal, Bone Morphogenetic Proteins (BMPs), Growth 
and Differentiation Factors (GDFs) and anti-Müllerian hormone (AMH). They act by regulating various develop-
mental and homeostatic processes and are involved in numerous human diseases49 as well as being considered a 
viable therapeutic target; nevertheless their pleiotropic signalling has resulted in limited success in targeting their 
activity. New insights provided herein suggest that miR302 plays a critical role in regulating epigenetic phenom-
ena that control cell fate.
Diabetes mellitus is a complex metabolic disorder characterised by persistent hyperglycaemia; emerging evi-
dence indicates that multiple factors involved in the aetiology of diabetes can alter epigenetic mechanisms and 
regulate susceptibility to microvascular complications. Particularly important is the role of the PRC2 methyl-
transferase, EZH2. EZH2 is the catalytic subunit of the PRC2 complex which catalyses the trimethylation of 
lysine 27 on the histone H3 and mediates genes silencing29. It is involved in repressing the E-cadherin promoter 
during EMT and its expression correlates with invasiveness and aggressiveness in multiple types of cancers35. 
In the present study we investigated the role that miR302 plays in acquired plasticity in primary human mesan-
gial cells. HMCs are significantly affected during renal diseases and these alterations lead to the expansion of 
Figure 5. miR302-HMCs acquire plasticity without gaining a tumorigenic phenotype. Typical markers of 
cancer have been investigated in order to gain more insight into miR302-HMCs phenotype. NFκ B, a potent 
driver of carcinogenesis and inflammation, is dramatically downregulated in miR302-HMCs (A), while p16, 
a well-known tumour suppressor protein is maintained in miR302-HMCs (B). Despite the upregulation of 
Snail, no TGFβ increase is detected at any of the time points analysed (C). To test whether miR302-HMCs 
were protected against apoptosis, we treated the cells with 50 μ M of etoposide for 24 h (D). No difference is 
detected in the expression of p53 and the cleaved form of caspase 3 in miR302, scramble and non-treated cells. 
(*P < 0.05). All panels are representative of 3 independent experiments.
www.nature.com/scientificreports/
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mesangial compartment and extracellular matrix deposition9,50. Our findings demonstrated an unexpected role 
for the miR302 family as part of a regulatory loop that controls cellular plasticity.
Previous analysis carried out in our laboratory demonstrated that miR302 is upregulated in HMCs under-
going a process of acquired, pro-fibrotic plasticity4. This might seem counterintuitive considering that its upreg-
ulation is triggered by CTGF stimulation, which is widely accepted to work in concert with TGFβ to activate 
fibrosis51 and impacts directly on the TGFβ pathway. Intrigued by these findings, we investigated the role that 
Figure 6. miR302-HMCs form ZO-1 containing junctions when cultured on matrigel. (A) Representative 
picture of normal, scramble and miR302 cells plated on matrigel. Original magnification x100. Mir302-HMCs 
show de novo expression of ZO-1 protein (C, white arrow), while they lose the expression of Snail, a marker 
of mesenchymal cells (B). (CTRL: control, HKC8s treated with TGFβ for 24 hrs). Furthermore they show 
upregulation of CDH1 (E-cadherin) expression at mRNA level (D), in particular when treated with DZnep 
(CTRL: control, HKC8). Original magnification x630. (DAPI: 4′ ,6-diamidino-2-phenylindole). (***P < 0.001).
www.nature.com/scientificreports/
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miR302 plays in HMC plasticity. During miR302 mediated differentiation, we found persistently high levels of 
Snail even after a decline in mRNA. In contrast, scramble control cells always exhibited low levels of mRNA and 
no protein was detectable. This likely reflects the dynamic nature of the reprogramming process where cells are 
likely to be asynchronous. In addiction, overexpression of miR302 in HMCs causes a strong upregulation of Slug, 
another member of the Snail family. Snail and Slug are both considered master regulators of the EMT process. 
This observation is important, since normally miR302 overexpressing cells are prevented from activating Smad3 
and Smad2 upon TGFβ stimulation4. Nevertheless, increased Snail expression is driven by miR302 in various cell 
types, consistent across both epithelial and mesenchymal phenotypes (Fig. 1 and Supplementary Fig. S5), point-
ing toward a TGFβ independent upregulation of the two TFs triggered by miR302. These two transcription factors 
have been recently implicated in iPSC generation32,52,53. In particular, Snail is required during the initial phase 
of reprogramming in order for the cells to acquire a higher degree of plasticity, by supressing Let-7 expression32, 
while Slug is pivotal in the later phases, although acting independently of its role as an EMT-transcription factor52. 
Interestingly, miR302 and Let-7 have essentially opposing roles during embryonic development, where miR302 
identifies pluripotent stem cells whereas Let-7 is highly expressed in differentiated cells13.
EMT involves distinct phenotypic changes through which a polarized epithelial cell gains a scattered mes-
enchymal phenotype, increasing its motility and invasion properties. A recent paper from the group of Nieto33 
points out that within injured renal parenchyma, tubular epithelial cells undergo a partial EMT, gaining a hybrid 
phenotype, in which they acquire Snail expression while maintaining their epithelial hallmarks. According to 
the authors, this partial EMT of the renal epithelial cells is able to trigger the release of inflammatory and fibrotic 
cytokines, such as TGFβ , in the microenvironment of the injured kidney leading to the development of fibrosis. 
Interestingly, HMCs overexpressing miR302 in an in vitro healthy context do not become more fibrotic, as indi-
cated by the lack of NFκ B expression and TGFβ mRNA. As Snail has been implicated in repressing the expression 
of Let-7, we analysed the level of expression of Let-7a and c, finding no correlation at early time points post trans-
duction (Fig. 2D). This is perhaps not surprising as the processes of iPSC generation and acquisition of plasticity 
by HMCs, although having some common ground, remain substantially different. The finding that Smad3 is 
present and phosphorylated in the nuclei of miR302-HMCs, despite the silencing of the receptor, is intriguing. 
This suggests that Smad3 is required by cells as an adaptor for phenotypic transition, as its knock down results 
in the decreased levels of EZH2. Indeed, other TGFβ family members have been proposed to signal in a similar 
manner; for example Smads likely direct Jmjd3 to target genes in ESCs and during differentiation via direct 
interaction in response to nodal/activin and facilitating target gene de-repression during endodermal specifica-
tion54. Furthermore, this points to a functional association between the two proteins, even though the expression 
relationship is not reciprocal as EZH2 knockdown does not affect Smad3 expression. This result supports recent 
findings from our laboratory that demonstrate a direct interaction between EZH2 and Smad346. Recent work 
from the Kaji group, demonstrated that the activated forms of Smad3 and Smad2 are not only required during 
iPSC generation but also promote the direct reprogramming of cells into a different type55. Moreover, the use of 
the SB431542, an inhibitor of the Tβ RI, during somatic cell reprogramming, enhances the acquisition of pluripo-
tency and in the absence of TGFβ stimulation causes an increase in the level of Smad3/2 phosphorylation, results 
in line with our observations.
HMCs were found to increase their rate of proliferation with EZH2 overexpression. It has been proposed 
that EZH2 may play a role independent of its activity in the PRC2 complex56. In the present study we confirmed 
that EZH2 expression is upregulated in miR302-HMCs however the methylation of lysine 27 of histone H3 is 
decreased (Fig. 3). Interestingly, we recently demonstrated a direct interaction between Smad3 and EZH2 during 
neuroepithelial differentiation57. Silencing of the type II TGFβ receptor by miR302 likely perturbs the interaction 
with EZH2 while the addition of DZnep erases the H3K27me3 mark, leading to the derepression of epithelial 
genes as evidenced by de novo detection and expression of ZO-1 and E-cadherin in miR302-HMCs. As EZH2 
and Snail show the same trend of expression we expected to find a reciprocal interaction between the two of 
them; however we clearly demonstrated that the lack of EZH2 does not impair Snail expression and vice versa. 
Nevertheless, these two proteins co-operate to control the acquisition of plasticity in HMCs, as evidenced by 
de novo expression of ZO-1 and E-cadherin, suggestive of MET.
In summary, the complex signalling systems that regulate the acquisition of plasticity in mesangial cells have 
clear parallels with the processes controlling pluripotency and are likely mediated by a small number of transcrip-
tional master regulators including Smad3 and Snail. Increased miR302 is sufficient to drive cells towards a highly 
plastic “hybrid” state in which they are susceptible to microenvironmental cues and differentiation. Further 
understanding of the intricate interplay between TGFβ receptors, Smad3, Snail and EZH2 will not only increase 
our knowledge of epigenetic and pathogenic processes in diverse diseases such as diabetes and cancer, but will 
point towards new therapeutic approaches focused on the exploitation and control of cellular plasticity (Fig. 7).
Material and Methods
Cell culture, viral transduction, TGFβ and inhibitor treatments of HMCs. Primary HMCs (Human 
Mesangial Cells; Lonza) were maintained in MCDB-131 medium (Gibco) while Human Kidney Cells (HKC8) 
were maintained in regular DMEM (Gibco), both supplemented with 10% (v/v) heat-inactivated Fetal Bovine 
Serum (FBS, Life Technologies), 10 mM L-glutamic acid (Gibco) and 100 U/ml penicillin and 100 μ g/ml strep-
tomycin (Gibco). For TGFβ stimulation, HMCs and HKC8 were serum starved for 24 h. Recombinant human 
TGFβ 1 (Promokine) was used at a final concentration of 5 ng/ml and cells were stimulated for 24 h, 48 h and 72 h. 
Protein and RNA were harvested at each time points. 3-Deazaneplanocin A (DZNep, Calbiochem) was added 1 h 
before TGFβ at a final concentration of 5 μ M.
For viral transduction, HMCs and HKC8 were seeded at 5 × 104 cells/well. The following day cells were trans-
duced with a lentivirus carrying the human miR302a/b/c/d cluster (System Biosciences) or a scramble sequence 
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(pGiPz). The media was changed 48 h post transduction and replaced with DMEM-F12 (Sigma) supplemented 
with 10% v/v FBS, 10 Mm L-glutamine, 100 U/ml penicillin and 100 μ g/ml streptomycin. The successfully trans-
duction was verified through GFP expression. Non-transduced HMCs and HKC8 maintained in DMEM-F12 
were used as a positive control.
The treatment with the SB431542 (Calbiochem) compound was carried out at 7 days post transduction 
for either 7 days (day 14 post transduction) or 14 days (day 21 post transduction) in mir302-HMCs scramble 
infected HMCs and non-treated HMCs. The final concentration was 10 μ M, media was changed every other day, 
no splitting was performed during the inhibitor treatment. Protein and RNA were extracted at day 7 and 14 post 
treatment.
Differentiation protocol. 7 days after viral transduction miR302 and scrambled-infected HMCs 
were adapted to KnockOut™ Serum Replacement (Thermo Fisher Scientific) media for 5 days. At day 13 
post-transduction the cells were trypsinized and plated on matrigel in the following media: DMEM-F12, 20% 
KnockOut™ Serum Replacement, 0.01 mM non-essential amino acid (NEAA, Gibco), 100 U/ml penicillin, 
100 μ g/ml streptomycin, 0.05 mM 2-mercaptoethanol (Sigma), 25-ng/ml bFGF (BioLegends) plus and minus 
0.1 μ M DZNep. The cells were maintained in culture for up to a week.
Matrigel coating. Growth-factor reduced matrigel (BD Bioscience) was prepared by diluting the matrigel 
in a ratio of 1:10 with cold serum-free media. The matrigel was washed three times in the plate and then the plate 
was incubated with the lid off for 30 minutes at room temperature inside the laminar hood. The plate was then 
incubated at 37 °C for 1 hour and washed one time with serum-free media before cells were seeded onto the plate.
Picking and culturing of HMC-colonies. After their initial appearance, colonies morphologically 
resembling ES colonies were picked and subcultured. Briefly, individual colonies were subcultured on matrigel 
in ES cell medium comprising Murine Embryonic Fibroblasts (MEFs) conditioned media, 20% KnockOut™ 
Serum Replacement, 0.01 mM non-essential amino acid, 100 U/ml penicillin, 100 μ g/ml streptomycin, 0.05 mM 
2-mercaptoethanol, 25-ng/ml bFGF. The colonies were cultured for up to 21 days.
Analysis of mRNA expression. Total RNA was extracted from HMCs at days 3, 7, 14, 21 and 28 
post-transduction according to the manufacturer’ s instruction (TRIzol® , Life Technologies). cDNA was synthe-
sized starting from 500 ng of RNA as previously described58. Quantitative RealTime PCR was performed using 
TaqMan assays for Tβ RII, Snail and CDH1. Data was normalized using 18 S as endogenous control.
microRNA analysis. Total RNA was extracted from HMCs at day 7 post-transduction according to the 
manufacturer’s instruction (TRIzol® , Life Technologies). cDNA was synthesized using TaqMan qRT-PCR assay 
for miR302 d, Let-7c and Let-7a. Data was normalized using RNU6B as endogenous control.
Western Blot analysis and nuclear-cytoplasmic fractionation. Total protein was isolated 
from HMCs at day 3, 7, 14, 21 and 28 using RIPA buffer (Tris-HCL, NaCl, NP-40, Na-deoxycholate, and 
Ethylenediaminetetraacetic acid (EDTA)) supplemented with 1 mM NaF, 1 mM Na2VO4, 50 mM phenyl-
methylsulphonylfluoride (PMSF) and protease and phosphatase inhibitor cocktails (Sigma). Nuclear-cytoplasmic 
Figure 7. Working hypothesis. Upon miR302 overexpression, HMCs acquired an enhanced plasticity, 
becoming highly responsive to the surrounding microenvironment (plastic hybrid cells). During this process 
the cells upregulate the expression of both Snail and EZH2. At this critical tipping point if these cells are 
placed under the appropriate stimuli, they can acquire epithelial characteristics or, potentially, other kind of 
phenotypes (question marks). This very dynamic process can be potentially blocked or reversed.
www.nature.com/scientificreports/
1 1Scientific RepoRts | 7:42407 | DOI: 10.1038/srep42407
fractionation of HMCs was achieved by suspending the cells in an isotonic buffer containing 10 mM HEPES, 
1.5 mM MgCl2, 10 mM KCl, 0.5 mM Dithiothreitol (DTT) and protease inhibitor cocktails, left on ice for 15 min 
to separate the nuclei from the cytoplasm and then centrifuged for 1 min at 12,000 × g at 4 °C. Nuclear pellets 
were then resuspended in a solution containing 20 mM HEPES, 25% v/v Glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 
0.2 mM EDTA, 05 mM PMSF, 0.5 mM DTT and protease inhibitor. The solution was then incubated for 30 min 
on a shaker at 4 °C and subsequently centrifuged. Total protein concentration was determined by Bradford Assay 
(Biorad). The following primary antibodies were used: Snail, Slug, Tβ RII, GAPDH, NFκ B, caspase 3, Smad3/P 
(all from Cell Signalling Technologies), E-Cadherin (BD pharmingen), EZH2 (kind gift from the Bracken 
Laboratory, Trinity College Dublin, Ireland), SUZ12 (Cell Signalling), p53 (Calbiochem), β -actin (Sigma), 
Histone 3 and H3K27 (all from Abcam).
Immunofluorescence staining. HMCs were fixed with 4% paraformaldehyde for 10 minutes, followed by 
1 h incubation at room temperature with rabbit polyclonal anti-ZO-1 (Invitrogen) primary antibody diluted in 
5% Goat Serum (Sigma). Goat anti-rabbit Texas Red (Invitrogen) was used as secondary antibody and incubated 
for 1 h at room temperature. Nuclei were counterstained with DAPI (4,6 diamidino-2-phenylindole, Sigma).
Proliferation and apoptosis assay. At day 7 and 21 post-transduction, HMCs were seeded onto a 96-well 
plate at a concentration of 500 cells/well. Non-transduced HMCs were seeded at the same concentration, as a 
control. 10 μ l of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide, Sigma) diluted in ddH2O 
(5 mg/ml) was added to each well, and the plate was incubated at 37 °C for 4 hours. Following incubation, 100 μ l 
of dimethyl sulphoxide (DMSO, Sigma) was added to each well. Optical Density (OD) was read at 570 nm and 
650 nm with an ELISA reader (Molecular Devices). In one set of experiments cells were treated at the time of the 
seeding with 5 μ M DZnep.
To trigger apoptosis, HMCs were incubated with 50 μ M of etoposide (Merck) for 24 h as follow. At day 7 post 
transduction miR302, scramble and non-transduced cells were seeded at confluency of 50%. The day after the 
cells were gently washed with PBS (Sigma) and fresh media was added along with 50 μ M of etoposide. The cells 
were lysed in RIPA buffer after 24 h.
Gene Knock down using the esiRNA technology. Endoribonuclease-prepared siRNA (esiRNA) were 
prepared as described by Heninger and Buchholz59, with a few modifications. In brief, cDNA was isolated from 
NT2 cells and used as a template from which to generate T7 RNA polymerase promoter-flanked cDNA frag-
ments, through two rounds of PCR amplification. These fragments represented the region of mRNA against 
which the esiRNAs would target genes of interest. These fragments were subsequently transcribed in vitro to 
generate double-stranded RNA (dsRNA) of the target amplicons, which were purified to isolate only larger 
(> 250 bp) RNA molecules. Following purification, dsRNA was digested using a Ribonuclease III (RNase III) 
mutant with a single amino acid substitution (E38A), which was produced in Escherichia coli60 to generate a hete-
rozygous population of ~21 nt siRNAs, capable of targeting multiple regions of target mRNA. Post-digestion, the 
siRNA fragments were purified using a QIAGEN RNeasy kit using high ethanol concentrations. See table 1 for a 
complete list of primers.
miR302, scramble (Firefly luciferase) and non-transduced HMCs as control, were transfected using 
Lipofectamine® 2000 (Invitrogen) according to manufacturer’s instruction 7 days post viral transduction. 48 h 
after transfection the cells were lysate for protein extraction.
Statistical analysis. The reported values were represented as the mean ± standard error of mean. One-way 
Anova and Bonferroni post-test were used to calculate the statistical significance for the analysis of more than 
two categories, Student’s t-test was used in the charts were only 2 categories are presented (*P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001). All the analyses were performed with PRISM5.02 (GraphPad Software Inc, La Jolla 
CA, USA).
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